{"pmid":32441783,"title":"A rationale for targeting the P2X7 receptor in Coronavirus disease 19 (Covid-19).","text":["A rationale for targeting the P2X7 receptor in Coronavirus disease 19 (Covid-19).","Severe pneumonia which shares several of the features of acute respiratory distress syndrome (ARDS) is the main cause of morbidity and mortality in Coronavirus disease 19 (Covid-19) for which as of now there is no effective treatment. ARDS is caused and sustained by an uncontrolled inflammatory activation characterized by a massive release of cytokines (cytokine storm), diffuse lung edema, inflammatory cell infiltraton and disseminated coagulation. Macrophage and T lymphocyte dysfunction plays a central role in this syndrome. In several experimental in vitro and in vivo models, many of these pathophysiological changes are triggered by stimulation of the P2X7 receptor. We hypothesize that this receptor might be an ideal candidate to target in Covid-19-associated severe pneumonia.","Br J Pharmacol","Di Virgilio, Francesco","Tang, Yong","Sarti, Alba Clara","Rossato, Marco","32441783"],"abstract":["Severe pneumonia which shares several of the features of acute respiratory distress syndrome (ARDS) is the main cause of morbidity and mortality in Coronavirus disease 19 (Covid-19) for which as of now there is no effective treatment. ARDS is caused and sustained by an uncontrolled inflammatory activation characterized by a massive release of cytokines (cytokine storm), diffuse lung edema, inflammatory cell infiltraton and disseminated coagulation. Macrophage and T lymphocyte dysfunction plays a central role in this syndrome. In several experimental in vitro and in vivo models, many of these pathophysiological changes are triggered by stimulation of the P2X7 receptor. We hypothesize that this receptor might be an ideal candidate to target in Covid-19-associated severe pneumonia."],"journal":"Br J Pharmacol","authors":["Di Virgilio, Francesco","Tang, Yong","Sarti, Alba Clara","Rossato, Marco"],"date":"2020-05-23T11:00:00Z","year":2020,"_id":"32441783","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1111/bph.15138","locations":["vivo"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667535119556018177,"score":9.490897,"similar":[{"pmid":32471272,"title":"Cannabinoid Receptor Type 2: A Possible Target in SARS-CoV-2 (CoV-19) Infection?","text":["Cannabinoid Receptor Type 2: A Possible Target in SARS-CoV-2 (CoV-19) Infection?","In late December 2019, a novel coronavirus (SARS-CoV-2 or CoV-19) appeared in Wuhan, China, causing a global pandemic. SARS-CoV-2 causes mild to severe respiratory tract inflammation, often developing into lung fibrosis with thrombosis in pulmonary small vessels and causing even death. COronaVIrus Disease (COVID-19) patients manifest exacerbated inflammatory and immune responses, cytokine storm, prevalence of pro-inflammatory M1 macrophages and increased levels of resident and circulating immune cells. Men show higher susceptibility to SARS-CoV-2 infection than women, likely due to estrogens production. The protective role of&nbsp;estrogens, as well as an immune-suppressive activity that limits the excessive inflammation, can be mediated by cannabinoid receptor type 2 (CB2). The role of this receptor in modulating inflammation and immune response is well documented in fact in several settings. The stimulation of CB2 receptors is known to limit the release of pro-inflammatory cytokines, shift the macrophage phenotype towards the anti-inflammatory M2 type and enhance the immune-modulating properties of mesenchymal stromal cells. For these reasons, we hypothesize that CB2 receptor can be a therapeutic target in COVID-19 pandemic emergency.","Int J Mol Sci","Rossi, Francesca","Tortora, Chiara","Argenziano, Maura","Di Paola, Alessandra","Punzo, Francesca","32471272"],"abstract":["In late December 2019, a novel coronavirus (SARS-CoV-2 or CoV-19) appeared in Wuhan, China, causing a global pandemic. SARS-CoV-2 causes mild to severe respiratory tract inflammation, often developing into lung fibrosis with thrombosis in pulmonary small vessels and causing even death. COronaVIrus Disease (COVID-19) patients manifest exacerbated inflammatory and immune responses, cytokine storm, prevalence of pro-inflammatory M1 macrophages and increased levels of resident and circulating immune cells. Men show higher susceptibility to SARS-CoV-2 infection than women, likely due to estrogens production. The protective role of&nbsp;estrogens, as well as an immune-suppressive activity that limits the excessive inflammation, can be mediated by cannabinoid receptor type 2 (CB2). The role of this receptor in modulating inflammation and immune response is well documented in fact in several settings. The stimulation of CB2 receptors is known to limit the release of pro-inflammatory cytokines, shift the macrophage phenotype towards the anti-inflammatory M2 type and enhance the immune-modulating properties of mesenchymal stromal cells. For these reasons, we hypothesize that CB2 receptor can be a therapeutic target in COVID-19 pandemic emergency."],"journal":"Int J Mol Sci","authors":["Rossi, Francesca","Tortora, Chiara","Argenziano, Maura","Di Paola, Alessandra","Punzo, Francesca"],"date":"2020-05-31T11:00:00Z","year":2020,"_id":"32471272","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.3390/ijms21113809","keywords":["covid-19","sars-cov-2","cannabinoid receptor type 2","endocannabinoids system","immune response","inflammation","molecular target","therapeutic strategies"],"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668255193299419136,"score":251.80434},{"pmid":32413619,"title":"beta-Glucan extracts from the same edible shiitake mushroom Lentinus edodes produce differential in-vitro immunomodulatory and pulmonary cytoprotective effects - Implications for coronavirus disease (COVID-19) immunotherapies.","text":["beta-Glucan extracts from the same edible shiitake mushroom Lentinus edodes produce differential in-vitro immunomodulatory and pulmonary cytoprotective effects - Implications for coronavirus disease (COVID-19) immunotherapies.","Coronavirus pneumonia is accompanied by rapid virus replication, where a large number of inflammatory cell infiltration and cytokine storm may lead to acute lung injury, acute respiratory distress syndrome (ARDS) and death. The uncontrolled release of pro-inflammatory cytokines, including interleukin (IL)-1beta and IL-6, is associated with ARDS. This constituted the first study to report on the variability in physicochemical properties of beta-glucans extracts from the same edible mushroom Lentinus edodes on the reduction of these pro-inflammatory cytokines and oxidative stress. Specifically, the impact on the immunomodulatory and cytoprotective properties of our novel in 'house' (IH-Lentinan, IHL) and a commercial (Carbosynth-Lentinan, CL) Lentinan extract were investigated using in vitro models of lung injury and macrophage phagocytosis. CL comprised higher amounts of alpha-glucans and correspondingly less beta-glucans. The two lentinan extracts demonstrated varying immunomodulatory activities. Both Lentinan extracts reduced cytokine-induced NF-kappaB activation in human alveolar epithelial A549 cells, with the IHL extract proving more effective at lower doses. In contrast, in activated THP-1 derived macrophages, the CL extract more effectively attenuated pro-inflammatory cytokine production (TNF-alpha, IL-8, IL-2, IL-6, IL-22) as well as TGF-beta and IL-10. The CL extract attenuated oxidative stress-induced early apoptosis, while the IHL extract attenuated late apoptosis. Our findings demonstrate significant physicochemical differences between Lentinan extracts, which produce differential in vitro immunomodulatory and pulmonary cytoprotective effects that may also have positive relevance to candidate COVID-19 therapeutics targeting cytokine storm.","Sci Total Environ","Murphy, Emma J","Masterson, Claire","Rezoagli, Emanuele","O'Toole, Daniel","Major, Ian","Stack, Gary D","Lynch, Mark","Laffey, John G","Rowan, Neil J","32413619"],"abstract":["Coronavirus pneumonia is accompanied by rapid virus replication, where a large number of inflammatory cell infiltration and cytokine storm may lead to acute lung injury, acute respiratory distress syndrome (ARDS) and death. The uncontrolled release of pro-inflammatory cytokines, including interleukin (IL)-1beta and IL-6, is associated with ARDS. This constituted the first study to report on the variability in physicochemical properties of beta-glucans extracts from the same edible mushroom Lentinus edodes on the reduction of these pro-inflammatory cytokines and oxidative stress. Specifically, the impact on the immunomodulatory and cytoprotective properties of our novel in 'house' (IH-Lentinan, IHL) and a commercial (Carbosynth-Lentinan, CL) Lentinan extract were investigated using in vitro models of lung injury and macrophage phagocytosis. CL comprised higher amounts of alpha-glucans and correspondingly less beta-glucans. The two lentinan extracts demonstrated varying immunomodulatory activities. Both Lentinan extracts reduced cytokine-induced NF-kappaB activation in human alveolar epithelial A549 cells, with the IHL extract proving more effective at lower doses. In contrast, in activated THP-1 derived macrophages, the CL extract more effectively attenuated pro-inflammatory cytokine production (TNF-alpha, IL-8, IL-2, IL-6, IL-22) as well as TGF-beta and IL-10. The CL extract attenuated oxidative stress-induced early apoptosis, while the IHL extract attenuated late apoptosis. Our findings demonstrate significant physicochemical differences between Lentinan extracts, which produce differential in vitro immunomodulatory and pulmonary cytoprotective effects that may also have positive relevance to candidate COVID-19 therapeutics targeting cytokine storm."],"journal":"Sci Total Environ","authors":["Murphy, Emma J","Masterson, Claire","Rezoagli, Emanuele","O'Toole, Daniel","Major, Ian","Stack, Gary D","Lynch, Mark","Laffey, John G","Rowan, Neil J"],"date":"2020-05-16T11:00:00Z","year":2020,"_id":"32413619","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.scitotenv.2020.139330","keywords":["covid-19","cytokine storm","disease mitigation","immunomodulation","medicinal mushroom","beta-glucans"],"locations":["Carbosynth-Lentinan","Lentinan","Lentinan","Lentinan","beta-Glucan"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666897319252983808,"score":248.58893},{"pmid":32446778,"title":"The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system.","text":["The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system.","In 2019-2020 a new coronavirus named SARS-CoV-2 was identified as the causative agent of a several acute respiratory infection named COVID-19, which is causing a worldwide pandemic. There are still many unresolved questions regarding the pathogenesis of this disease and especially the reasons underlying the extremely different clinical course, ranging from asymptomatic forms to severe manifestations, including the Acute Respiratory Distress Syndrome (ARDS). SARS-CoV-2 showed phylogenetic similarities to both SARS-CoV and MERS-CoV viruses, and some of the clinical features are shared between COVID-19 and previously identified beta-coronavirus infections. Available evidence indicate that the so called \"cytokine storm\" an uncontrolled over-production of soluble markers of inflammation which, in turn, sustain an aberrant systemic inflammatory response, is a major responsible for the occurrence of ARDS. Chemokines are low molecular weight proteins with powerful chemoattractant activity which play a role in the immune cell recruitment during inflammation. This review will be aimed at providing an overview of the current knowledge on the involvement of the chemokine/chemokine-receptor system in the cytokine storm related to SARS-CoV-2 infection. Basic and clinical evidences obtained from previous SARS and MERS epidemics and available data from COVID-19 will be taken into account.","Cytokine Growth Factor Rev","Coperchini, Francesca","Chiovato, Luca","Croce, Laura","Magri, Flavia","Rotondi, Mario","32446778"],"abstract":["In 2019-2020 a new coronavirus named SARS-CoV-2 was identified as the causative agent of a several acute respiratory infection named COVID-19, which is causing a worldwide pandemic. There are still many unresolved questions regarding the pathogenesis of this disease and especially the reasons underlying the extremely different clinical course, ranging from asymptomatic forms to severe manifestations, including the Acute Respiratory Distress Syndrome (ARDS). SARS-CoV-2 showed phylogenetic similarities to both SARS-CoV and MERS-CoV viruses, and some of the clinical features are shared between COVID-19 and previously identified beta-coronavirus infections. Available evidence indicate that the so called \"cytokine storm\" an uncontrolled over-production of soluble markers of inflammation which, in turn, sustain an aberrant systemic inflammatory response, is a major responsible for the occurrence of ARDS. Chemokines are low molecular weight proteins with powerful chemoattractant activity which play a role in the immune cell recruitment during inflammation. This review will be aimed at providing an overview of the current knowledge on the involvement of the chemokine/chemokine-receptor system in the cytokine storm related to SARS-CoV-2 infection. Basic and clinical evidences obtained from previous SARS and MERS epidemics and available data from COVID-19 will be taken into account."],"journal":"Cytokine Growth Factor Rev","authors":["Coperchini, Francesca","Chiovato, Luca","Croce, Laura","Magri, Flavia","Rotondi, Mario"],"date":"2020-05-25T11:00:00Z","year":2020,"_id":"32446778","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1016/j.cytogfr.2020.05.003","keywords":["covid-19","cxcl10","cxcl8","chemokines","coronavirus","cytokine storm"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667698385850728449,"score":232.01964},{"pmid":32434788,"title":"COVID-19 and lung cancer: risks, mechanisms and treatment interactions.","text":["COVID-19 and lung cancer: risks, mechanisms and treatment interactions.","Cases of the 2019 novel coronavirus also known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continue to rise worldwide. To date, there is no effective treatment. Clinical management is largely symptomatic, with organ support in intensive care for critically ill patients. The first phase I trial to test the efficacy of a vaccine has recently begun, but in the meantime there is an urgent need to decrease the morbidity and mortality of severe cases. It is known that patients with cancer are more susceptible to infection than individuals without cancer because of their systemic immunosuppressive state caused by the malignancy and anticancer treatments. Therefore, these patients might be at increased risk of pulmonary complications from COVID-19. The SARS-CoV-2 could in some case induce excessive and aberrant non-effective host immune responses that are associated with potentially fatal severe lung injury and patients can develop acute respiratory distress syndrome (ARDS). Cytokine release syndrome and viral ARDS result from uncontrolled severe acute inflammation. Acute lung injury results from inflammatory monocyte and macrophage activation in the pulmonary luminal epithelium which lead to a release of proinflammatory cytokines including interleukin (IL)-6, IL-1 and tumor necrosis factor-alpha. These cytokines play a crucial role in immune-related pneumonitis, and could represent a promising target when the infiltration is T cell predominant or there are indirect signs of high IL-6-related inflammation, such as elevated C-reactive protein. A monoclonal anti-IL-6 receptor antibody, tocilizumab has been administered in a number of cases in China and Italy. Positive clinical and radiological outcomes have been reported. These early findings have led to an ongoing randomized controlled clinical trial in China and Italy. While data from those trials are eagerly awaited, patients' management will continue to rely for the vast majority on local guidelines. Among many other aspects, this crisis has proven that different specialists must join forces to deliver the best possible care to patients.","J Immunother Cancer","Addeo, Alfredo","Obeid, Michel","Friedlaender, Alex","32434788"],"abstract":["Cases of the 2019 novel coronavirus also known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continue to rise worldwide. To date, there is no effective treatment. Clinical management is largely symptomatic, with organ support in intensive care for critically ill patients. The first phase I trial to test the efficacy of a vaccine has recently begun, but in the meantime there is an urgent need to decrease the morbidity and mortality of severe cases. It is known that patients with cancer are more susceptible to infection than individuals without cancer because of their systemic immunosuppressive state caused by the malignancy and anticancer treatments. Therefore, these patients might be at increased risk of pulmonary complications from COVID-19. The SARS-CoV-2 could in some case induce excessive and aberrant non-effective host immune responses that are associated with potentially fatal severe lung injury and patients can develop acute respiratory distress syndrome (ARDS). Cytokine release syndrome and viral ARDS result from uncontrolled severe acute inflammation. Acute lung injury results from inflammatory monocyte and macrophage activation in the pulmonary luminal epithelium which lead to a release of proinflammatory cytokines including interleukin (IL)-6, IL-1 and tumor necrosis factor-alpha. These cytokines play a crucial role in immune-related pneumonitis, and could represent a promising target when the infiltration is T cell predominant or there are indirect signs of high IL-6-related inflammation, such as elevated C-reactive protein. A monoclonal anti-IL-6 receptor antibody, tocilizumab has been administered in a number of cases in China and Italy. Positive clinical and radiological outcomes have been reported. These early findings have led to an ongoing randomized controlled clinical trial in China and Italy. While data from those trials are eagerly awaited, patients' management will continue to rely for the vast majority on local guidelines. Among many other aspects, this crisis has proven that different specialists must join forces to deliver the best possible care to patients."],"journal":"J Immunother Cancer","authors":["Addeo, Alfredo","Obeid, Michel","Friedlaender, Alex"],"date":"2020-05-22T11:00:00Z","year":2020,"_id":"32434788","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1136/jitc-2020-000892","keywords":["t-lymphocytes","immunity","lung neoplasms"],"locations":["Cytokine","China","Italy","China","Italy"],"countries":["China","Italy"],"countries_codes":["CHN|China","ITA|Italy"],"e_drugs":["tocilizumab"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667521393731829760,"score":218.60556},{"pmid":32385712,"title":"Inflammation resolution: a dual-pronged approach to averting cytokine storms in COVID-19?","text":["Inflammation resolution: a dual-pronged approach to averting cytokine storms in COVID-19?","Severe coronavirus disease (COVID-19) is characterized by pulmonary hyper-inflammation and potentially life-threatening \"cytokine storms\". Controlling the local and systemic inflammatory response in COVID-19 may be as important as anti-viral therapies. Endogenous lipid autacoid mediators, referred to as eicosanoids, play a critical role in the induction of inflammation and pro-inflammatory cytokine production. SARS-CoV-2 may trigger a cell death (\"debris\")-induced \"eicosanoid storm\", including prostaglandins and leukotrienes, which in turn initiates a robust inflammatory response. A paradigm shift is emerging in our understanding of the resolution of inflammation as an active biochemical process with the discovery of novel endogenous specialized pro-resolving lipid autacoid mediators (SPMs), such as resolvins. Resolvins and other SPMs stimulate macrophage-mediated clearance of debris and counter pro-inflammatory cytokine production, a process called inflammation resolution. SPMs and their lipid precursors exhibit anti-viral activity at nanogram doses in the setting of influenza without being immunosuppressive. SPMs also promote anti-viral B cell antibodies and lymphocyte activity, highlighting their potential use in the treatment of COVID-19. Soluble epoxide hydrolase (sEH) inhibitors stabilize arachidonic acid-derived epoxyeicosatrienoic acids (EETs), which also stimulate inflammation resolution by promoting the production of pro-resolution mediators, activating anti-inflammatory processes, and preventing the cytokine storm. Both resolvins and EETs also attenuate pathological thrombosis and promote clot removal, which is emerging as a key pathology of COVID-19 infection. Thus, both SPMs and sEH inhibitors may promote the resolution of inflammation in COVID-19, thereby reducing acute respiratory distress syndrome (ARDS) and other life-threatening complications associated with robust viral-induced inflammation. While most COVID-19 clinical trials focus on \"anti-viral\" and \"anti-inflammatory\" strategies, stimulating inflammation resolution is a novel host-centric therapeutic avenue. Importantly, SPMs and sEH inhibitors are currently in clinical trials for other inflammatory diseases and could be rapidly translated for the management of COVID-19 via debris clearance and inflammatory cytokine suppression. Here, we discuss using pro-resolution mediators as a potential complement to current anti-viral strategies for COVID-19.","Cancer Metastasis Rev","Panigrahy, Dipak","Gilligan, Molly M","Huang, Sui","Gartung, Allison","Cortes-Puch, Irene","Sime, Patricia J","Phipps, Richard P","Serhan, Charles N","Hammock, Bruce D","32385712"],"abstract":["Severe coronavirus disease (COVID-19) is characterized by pulmonary hyper-inflammation and potentially life-threatening \"cytokine storms\". Controlling the local and systemic inflammatory response in COVID-19 may be as important as anti-viral therapies. Endogenous lipid autacoid mediators, referred to as eicosanoids, play a critical role in the induction of inflammation and pro-inflammatory cytokine production. SARS-CoV-2 may trigger a cell death (\"debris\")-induced \"eicosanoid storm\", including prostaglandins and leukotrienes, which in turn initiates a robust inflammatory response. A paradigm shift is emerging in our understanding of the resolution of inflammation as an active biochemical process with the discovery of novel endogenous specialized pro-resolving lipid autacoid mediators (SPMs), such as resolvins. Resolvins and other SPMs stimulate macrophage-mediated clearance of debris and counter pro-inflammatory cytokine production, a process called inflammation resolution. SPMs and their lipid precursors exhibit anti-viral activity at nanogram doses in the setting of influenza without being immunosuppressive. SPMs also promote anti-viral B cell antibodies and lymphocyte activity, highlighting their potential use in the treatment of COVID-19. Soluble epoxide hydrolase (sEH) inhibitors stabilize arachidonic acid-derived epoxyeicosatrienoic acids (EETs), which also stimulate inflammation resolution by promoting the production of pro-resolution mediators, activating anti-inflammatory processes, and preventing the cytokine storm. Both resolvins and EETs also attenuate pathological thrombosis and promote clot removal, which is emerging as a key pathology of COVID-19 infection. Thus, both SPMs and sEH inhibitors may promote the resolution of inflammation in COVID-19, thereby reducing acute respiratory distress syndrome (ARDS) and other life-threatening complications associated with robust viral-induced inflammation. While most COVID-19 clinical trials focus on \"anti-viral\" and \"anti-inflammatory\" strategies, stimulating inflammation resolution is a novel host-centric therapeutic avenue. Importantly, SPMs and sEH inhibitors are currently in clinical trials for other inflammatory diseases and could be rapidly translated for the management of COVID-19 via debris clearance and inflammatory cytokine suppression. Here, we discuss using pro-resolution mediators as a potential complement to current anti-viral strategies for COVID-19."],"journal":"Cancer Metastasis Rev","authors":["Panigrahy, Dipak","Gilligan, Molly M","Huang, Sui","Gartung, Allison","Cortes-Puch, Irene","Sime, Patricia J","Phipps, Richard P","Serhan, Charles N","Hammock, Bruce D"],"date":"2020-05-10T11:00:00Z","year":2020,"_id":"32385712","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1007/s10555-020-09889-4","keywords":["covid-19","cytokine storms","eicosanoid storm","inflammation resolution","sars-cov-2"],"e_drugs":["Eicosanoids","Arachidonic Acid","Lipids","Prostaglandins","Leukotrienes"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666340102065881089,"score":209.96779}]}